Novel RING E3 ubiquitin ligases in breast cancer

Neoplasia

Volumn 8, Issue 8, 2006, Pages 689-695

  Burger, Angelika ^a,b,c   Amemiya, Yutaka ^a,b   Kitching, Richard ^a,b   Seth, Arun K ^a,b,d  

^a Sunnybrook Health Sciences Centre   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d Department of Anatomic Pathology   (Canada)

Author keywords

BCA2; Breast cancer; RING ligase; RNF11; Ubiquitin

Indexed keywords

BCA2 ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; RNF11 ENZYME; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; BCA2 PROTEIN, HUMAN; CARRIER PROTEIN; RNF11 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

AMINO ACID SEQUENCE; BREAST CANCER; DRUG MECHANISM; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; BREAST TUMOR; CANCER INVASION; FEMALE; GENETICS; METABOLISM; PATHOPHYSIOLOGY;

BREAST NEOPLASMS; CARRIER PROTEINS; FEMALE; HUMANS; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN-PROTEIN LIGASES;

EID: 33748570421     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06469     Document Type: Review

References (61)

1. Rock KL and Goldberg AL (1999). Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 17, 739-779.
2. Goldberg AL, Stein R, and Adams J (1995). New insights into proteasome function: from archaebacteria to drug development. Chem Biol 2 (8), 503-508.
3. Hicke L (2001). Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2 (3), 195-201.
4. Handley-Gearhart PM, Stephen AG, Trausch-Azar JS, Ciechanover A, and Schwartz AL (1994). Human ubiquitin-activating enzyme, E1. Indication of potential nuclear and cytoplasmic subpopulations using epitope-tagged cDNA constructs. J Biol Chem 269 (52), 33171-33178.
5. Burger AM and Seth AK (2004). The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer 40 (15), 2217-2229.
6. Nalepa G and Wade Harper J (2003). Therapeutic anti-cancer targets upstream of the proteasome. Cancer Treat Rev 29 (1), 49-57.
7. Weissman AM (2001). Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2 (3), 169-178.
8. Pray TR, Parlati F, Huang J, Wong BR, Payan DG, Bennett MK, Issakani SD, Molineaux S, and Demo SD (2002). Cell cycle regulatory E3 ubiquitin ligases as anticancer targets. Drug Resist Updat 5 (6), 249-258.
9. Joazeiro CAP and Wa M (2000). RING finger proteins: mediators of ubiquitin ligase activity. Cell 102, 549-552.
10. Hatakeyama S and Nakayama KI (2003). U-box proteins as a new family of ubiquitin ligases. Biochem Biophys Res Commun 302 (4), 635-645.
11. Mani A and Gelmann EP (2005). The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23 (21), 4776-4789.
12. Coscoy L and Ganem D (2003). PHD domains and E3 ubiquitin ligases: viruses make the connection. Trends Cell Biol 13 (1), 7-12.
13. Ohta T, Michel JJ, Schottelius AJ, and Xiong Y (1999). ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol Cell 3 (4), 535-541.
14. Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, Chu C, Koepp DM, Elledge SJ, Pagano M, et al. (2002). Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 416 (6882), 703-709.
15. Ohta T and Fukuda M (2004). Ubiquitin and breast cancer. Oncogene 23 (11), 2079-2088.
16. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, et al. (1997). Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer [see comments]. Nat Med 3 (2), 227-230.
17. Morgan DO (1999). Regulation of the APC and the exit from mitosis. Nat Cell Biol 1 (2), E47 -E53.
18. Burger AM, Gao Y, Amemiya Y, Kahn HJ, Kitching R, Yang Y, Sun P, Narod SA, Hanna WM, and Seth AK (2005). A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer. Cancer Res 65 (22), 10401-10412.
19. Dornan D, Bheddah S, Newton K, Ince W, Frantz GD, Dowd P, Koeppen H, Dixit VM, and French DM (2004). COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res 64 (20), 7226-7230.
20. Feki A, Jefford CE, Berardi P, Wu JY, Cartier L, Krause KH, and Irminger-Finger I. (2005). BARD1 induces apoptosis by catalysing phosphorylation of p53 by DNA-damage response kinase. Oncogene 24 (23), 3726-3736.
21. Brooks CL and Gu W (2006). p53 ubiquitination: Mdm2 and beyond. Mol Cell 21 (3), 307-315.
22. Onel K and Cordon-Cardo C (2004). MDM2 and prognosis. Mol Cancer Res 2 (1), 1-8.
23. Turbin DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De Luca A, Nielsen TO, Huntsman DG, and Gilks CB (2006). MDM2 protein expression is a negative prognostic marker in breast carcinoma. Mod Pathol 19 (1), 69-74.
24. Hori M, Shimazaki J, Inagawa S, and Itabashi M (2002). Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human gen breast cancer. Breast Cancer Res Treat 71 (1), 77-83.
25. Horie K, Urano T, Ikeda K, and Inoue S (2003). Estrogen-responsive RING finger protein controls breast cancer growth. J Steroid Biochem Mol Biol 85 (2-5), 101-104.
26. Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M, Ouchi Y, and Inoue S (2002). Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature 417 (6891), 871-875.
27. Suzuki T, Urano T, Tsukui T, Horie-Inoue K, Moriya T, Ishida T, Muramatsu M, Ouchi Y, Sasano H, and Inoue S (2005). Estrogen-responsive finger protein as a new potential biomarker for breast cancer. Clin Cancer Res 11 (17), 6148-6154.
28. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, and Liu YC (1999). The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 286 (5438), 309-312.
29. Levkowitz G, Oved S, Klapper LN, Harari D, Lavi S, Sela M, and Yarden Y (2000). c-Cbl is a suppressor of the neu oncogene. J Biol Chem 275 (45), 35532-35539.
30. Sridhar SS, Seymour L, and Shepherd FA (2003). Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4 (7), 397-406.
31. Klapper LN, Waterman H, Sela M, and Yarden Y (2000). Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 60 (13), 3384-3388.
32. Duan L, Miura Y, Dimri M, Majumder B, Dodge IL, Reddi AL, Ghosh A, Fernandes N, Zhou P, Mullane-Robinson K, et al. (2003). Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J Biol Chem 278 (31), 28950-28960.
33. Derynck R, Akhurst RJ, and Balmain A (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29 (2), 117-129.
34. Xie W, Mertens JC, Reiss DJ, Rimm DL, Camp RL, Haffty BG, and Reiss M (2002). Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res 62 (2), 497-505.
35. Kalkhoven E, Roelen BA, de Winter JP, Mummery CL, van den Eijnden-van Raaij AJ, van der Saag PT, and van der Burg B (1995). Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ 6 (9), 1151-1161.
36. Azhar M (2001). Non-redundant tumour suppressor functions of transforming growth factor beta in breast cancer. J Biosci 26 (1), 9-12.
37. Massague J, Blain SW, and Lo RS (2000). TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103 (2), 295-309.
38. Miyazono K, Maeda S, and Imamura T (2004). Coordinate regulation of cell growth and differentiation by TGF-beta superfamily and Runx proteins. Oncogene 23 (24), 4232-4237.
39. Kitching R, Gish G, Burger A, Landberg G, and Seth A (2003). The RING-H2 protein RNF11 is differentially expressed in breast tumors and interacts with HECT-type E3 ligases. Biochim Biophys Acta 1639, 104-112.
40. Li H-X and Seth A (2004). An RNF11:Smurf2 complex mediates ubiquitination of the AMSH protein. Oncogene 23 (10), 1801-1808.
41. Subramaniam V, Lubovitz J, Li H-X, Burger A, Kitching R, and Seth A (2003). The RING-H2 protein RNF11 is overexpressed in breast cancer and is a target of Smurf2 E3 ligase. Br J Cancer I89, 1538-1544.
42. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, Richardson MA, Topper JN, Gimbrone MA Jr, Wrana JL, et al. (1997). The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell 89 (7), 1165-1173.
43. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, and Wrana JL (2000). Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 6 (6), 1365-1375.
44. Herbst RS, Fukuoka M, and Baselga J (2004). Gefitinib - a novel targeted approach to treating cancer. Nat Rev Cancer 4 (12), 956-965.
45. Jiang X, Huang F, Marusyk A, and Sorkin A (2003). Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Mol Biol Cell 14 (3), 858-870.
46. Yamasaki S, Nishida K, Yoshida Y, Itoh M, Hibi M, and Hirano T (2003). Gab1 is required for EGF receptor signaling and the transformation by activated ErbB2. Oncogene 22 (10), 1546-1556.
47. Urbe S, Mills IG, Stenmark H, Kitamura N, and Clague MJ (2000). Endosomal localization and receptor dynamics determine tyrosine phosphorylation of hepatocyte growth factor-regulated tyrosine kinase substrate. Mol Cell Biol 20 (20), 7685-7692.
48. Raiborg C, Bache KG, Gillooly DJ, Madshus IH, Stang E, and Stenmark H (2002). Hrs sorts ubiquitinated proteins into clathrin-coated microdomains of early endosomes. Nat Cell Biol 4 (5), 394-398.
49. Haglund K, Sigismund S, Polo S, Szymkiewicz I, Di Fiore PP, and Dikic I (2003). Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol 5 (5), 461-466.
50. van Delft S, Govers R, Strous GJ, Verkleij AJ, and van Bergen en Henegouwen PM (1997). Epidermal growth factor induces ubiquitination of Eps15. J Biol Chem 272 (22), 14013-14016.
51. Confalonieri S, Salcini AE, Puri C, Tacchetti C, and Di Fiore PP (2000). Tyrosine phosphorylation of Eps15 is required for ligand-regulated, but not constitutive, endocytosis. J Cell Biol 150 (4), 905-912.
52. Bache KG, Raiborg C, Mehlum A, and Stenmark H (2003). STAM and Hrs are subunits of a multivalent ubiquitin-binding complex on early endosomes. J Biol Chem 278 (14), 12513-12521.
53. Asao H, Sasaki Y, Arita T, Tanaka N, Endo K, Kasai H, Takeshita T, Endo Y, Fujita T, and Sugamura K (1997). Hrs is associated with STAM, a signal-transducing adaptor molecule. Its suppressive effect on cytokine-induced cell growth. J Biol Chem 272 (52), 32785-32791.
54. Burger A, Li H, Zhang XK, Pienkowska M, Venanzoni M, Vournakis J, Papas T, and Seth A (1998). Breast cancer genome anatomy: correlation of morphological changes in breast carcinomas with expression of the novel gene product Di12. Oncogene 16 (3), 327-333.
55. Suzuki H, Fukunishi Y, Kagawa I, Saito R, Oda H, Endo T, Kondo S, Bono H, Okazaki Y, and Hayashizaki Y (2001). Protein-protein interaction panel using mouse full-length cDNAs. Genome Res 11 (10), 1758-1765.
56. Mizuno K, Kitamura A, and Sasaki T (2003). Rabring7, a novel Rab7 target protein with a RING finger motif. Mol Biol Cell 14 (9), 3741-3752.
57. Connor MK, Subramaniam V, Li H-X, and Seth A (2005). Molecular characterization of Ring-finger protein 11. Mol Cancer Res 3 (8), 453-461.
58. Lehner B, Semple JI, Brown SE, Counsell D, Campbell RD, and Sanderson CM (2004). Analysis of a high-throughput yeast two-hybrid system and its use to predict the function of intracellular proteins encoded within the human MHC class III region. Genomics 83 (1), 153-167.
59. Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Croughton K, Cruciat C, Eberhard D, Gagneur J, Ghidelli S, et al. (2004). A physical and functional map of the human TNF-alpha/NF-NF-kappa B signal transduction pathway. Nat Cell Biol 6 (2), 97-105.
60. Amemiya A, Burger A, and Seth A (2005). Molecular characterization of the BCA2 protein: a novel RING-type E3 ligase that is overexpressed in breast and prostate cancers. Proc Am Assoc Cancer Res 46, 2329.
61. Kosarev P, Mayer KF, and Hardtke CS (2002). Evaluation and classification of RING-finger domains encoded by the Arabidopsis genome. Genome Biol 3 (4), RESEARCH0016.